Notes to the Company financial statements For the year ended 31 December 2018 46.
Adoption of new and revised standards The impact on the Company of new and revised standards is the same as for the Group.
Details are given in note 1 to the consolidated financial statements.
Significant accounting policies Basis of accounting These financial statements, for the year ended 31 December 2018 have been prepared in accordance with FRS 101.
As permitted by FRS 101, the Company has taken advantage of the following exemptions from the requirements of IFRS as below: The following paragraphs of IAS 1, Presentation of Financial Statements: 10 d, statement of cash flows 16 statement of compliance with all IFRS 38A requirements for a minimum of two primary statements, including cash flow statements 45B and 46 to 52 share-based payment IFRS 7 financial instruments disclosure IAS 24 paragraph 17 IAS 8 paragraph 30 and 31 111 cash flow statement information : and IAS 7 Statement of Cash Flows.
We have considered the impact of IFRS 9.
The Company does not expect any credit losses from intra-Group receivables.
No individual profit and loss account is prepared as provided by section 408 of the Companies Act 2006.
The financial statements have been prepared on the historical cost basis.
The principle accounting policies adopted are the same as those set out in note 2 of the consolidated financial statements with the addition of the policies noted below.
Investments in subsidiaries are stated at cost less, where appropriate, provision for impairment.
There are no significant judgements and estimates affecting the financial statements of the Company.
The carrying value of investments are reviewed for impairment when there is an indication that the investments might be impaired.
Any provision resulting from an impairment review is charged to the income statement.
Equity-settled employee share scheme are accounted for in accordance with IFRS 2 Share-based payment.
The current charge expenses relating to the subsidiaries employees are recharged to subsidiary companies.
170 170 Hikma Pharmaceuticals PLC | Annual Report 2018 Financial statements 48.
Intangible assets Software Total $m $m Cost Balance at 1 January 2017 13 13 Additions 8 8 Balance at 1 January 2018 21 21 Additions 8 8 Transfer 2 2 Balance at 31 December 2018 27 27 Amortisation Balance at 1 January 2017 Charge for the year 1 1 Balance at 1 January 2018 1 1 Charge for the year 1 1 Impairment 2 2 Balance at 31 December 2018 4 4 Carrying amount At 31 December 2018 23 23 At 31 December 2017 20 20 Details of useful lives and amortisation rates are included in note 16.
Investments in subsidiaries The details of investment in subsidiaries are mentioned in note 41.
The following table provides the movement of the investments in subsidiaries: 2018 2017 $m $m Beginning balance 3,323 3,179 Additions to subsidiaries 5 144 Ending balance 3,328 3,323 171 Hikma Pharmaceuticals PLC | Annual Report 2018 171 Notes to the Company financial statements continued 50.
Due from subsidiaries Non-current assets 2018 2017 $m $m Hikma Pharmaceuticals USA Inc. 8 8 Hikma Italia S. P. A 1 4 Hikma Hong Kong 10 Hikma Pharmaceuticals International Limited 54 167 Hikma UK Limited 104 183 177 362 Current assets 2018 2017 $m $m Hikma Pharmaceuticals LLC 2 Hikma UK Limited 55 Hikma MENA Holdings Limited 19 5 Hikma Pharmaceuticals USA Inc. 9 4 Hikma Pharma SAE 4 3 Hikma Farmaceutica, Portugal S. A.
1 1 Hikma Emerging Markets and Asia Pacific FZ-LLC 5 3 Others 1 41 71 51.
Other current assets 2018 2017 $m $m Price adjustment receivable 20 61 Investments at FVTPL 2017: available-for-sale investments 21 22 Others 3 41 86 Price adjustment receivable in respect to note 24 this represents the current portion of the contingent receivable in relation to the Columbus business acquisition, whereby as part of the acquisition, the Group will be reimbursed for certain contingent payments in respect of milestones and other conditions based on future events.
During the year, the Group received $45 million reimbursement 2017: $3 million in cash.
The non-current portion of price adjustment receivable is included within other non-current assets note 19.
Investment at FVTPL represents the agreement the Group entered into with an asset management firm in 2015 to manage a $20 million portfolio of underlying debt instruments.
The investment comprises a portfolio of assets that are managed by an asset manager and is measured at fair value: any changes in fair value go through the income statement.
This asset is classified as level 1 as it uses quoted prices in active markets.
172 Hikma Pharmaceuticals PLC | Annual Report 2018 172 Financial statements 52.
Cash and cash equivalents As at 31 December 2018 2017 $m $m Cash at banks and on hand 7 5 Time deposits 43 20 50 25 Cash and cash equivalents include highly liquid investments with maturities of three months or less which are convertible to known amounts of cash and are subject to insignificant risk of changes in value.
Other payables Management consider that the carrying amount of other payables approximates to their fair value.
Due to subsidiaries Non-current liabilities 2018 2017 $m $m Hikma Maple Limited 44 Hikma Investment LLC 1 1 Hikma Pharmaceuticals LLC 10 Hikma MENA Holdings Limited 59 60 Hikma Pharma Limited 17 77 115 Current liabilities 2018 2017 $m $m Hikma Investment LLC 17 22 Hikma Pharmaceuticals International Limited 18 15 Hikma Pharma Limited 2 2 Hikma UK limited 2 39 39 55.
Long-term financial debts The balance comprises mainly of a $500 million carrying value of $497 million, and fair value of $496 million 4.25% Eurobond due in April 2020 with the rating of BB Ba1 and a withdrawal of $nil on the syndicated revolving credit facility note 29.
173 Hikma Pharmaceuticals PLC | Annual Report 2018 173 Notes to the Company financial statements continued 56.
Staff costs Hikma Pharmaceuticals PLC currently has an average of 36 employees 2017: 30 employees excluding Executive Directors : total compensation paid to them amounted to $10 million 2017: $8 million of which salaries and bonuses compromise an amount of $8 million 2017: $6 million the remaining balance of $2 million 2017: $2 million represents national insurance contributions.
Share capital Issued and fully paid included in shareholders equity: 2018 2017 Number $m Number $m At 1 January 240,678,894 40 239,954,532 40 Issued during the year Ordinary Shares of 10p each 776,500 724,362 At 31 December 241,455,394 40 240,678,894 40 58.
Share premium Share premium $m Balance at 1 January and 31 December 2018 282 59.
Loss profit for the year The net loss in the Company for the year is $16 million 2017: profit $12 million.
Included in the net loss for the year is an amount of $47 million 2017: $16 million representing dividends received and $4 million 2017: $5 million representing the current year charge of share-based payments.
The remaining income statement components represents general and administrative expenses and net financing expenses.
Audit fees for the Company are disclosed in note 7.
Contingent liabilities A contingent liability exists at the balance sheet date in respect to a standby letter of credit totalling $9 million 2017: $9 million for potential stamp duty obligation that may arise if a repayment of the syndicated revolving credit facility see note 29 is made by the intercompany guarantors on behalf of the Company.
It is not probable that the repayment will be made by the intercompany guarantors.
174 Hikma Pharmaceuticals PLC | Annual Report 2018 174
